A physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life
JF Schlender, D Teutonico, K Coboeken… - Clinical …, 2018 - Springer
Background Physiologically-based pharmacokinetic (PBPK) modeling has received growing
interest as a useful tool for the assessment of drug pharmacokinetics by continuous …
interest as a useful tool for the assessment of drug pharmacokinetics by continuous …
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of …
Abstract Background Drug–drug interactions (DDIs) and drug–gene interactions (DGIs) pose
a serious health risk that can be avoided by dose adaptation. These interactions are …
a serious health risk that can be avoided by dose adaptation. These interactions are …
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development
Whole-body physiologically based pharmacokinetic (WB-PBPK) models have become an
important tool in drug development, as they enable characterization of pharmacokinetic …
important tool in drug development, as they enable characterization of pharmacokinetic …
Defining end-user acceptability attributes of orodispersible films for patient centricity
M Scarpa - 2019 - discovery.ucl.ac.uk
Poor acceptability has been associated with low compliance, particularly in special patient
populations. Patient acceptability assessment of individual dosage form attributes offers the …
populations. Patient acceptability assessment of individual dosage form attributes offers the …
[图书][B] Mind the developmental gap: Identifying adverse drug effects across childhood to evaluate biological mechanisms from growth and development
NP Giangreco - 2022 - search.proquest.com
Adverse drug reactions are a leading cause of morbidity and mortality that costs billions of
dollars for the healthcare system. In children, there is increased risk for adverse drug …
dollars for the healthcare system. In children, there is increased risk for adverse drug …
Development of Drug Products for Older Adults: Challenges, Solutions, and Regulatory Considerations
SWJ Lau, DR Abernethy… - Drug Discovery and …, 2019 - taylorfrancis.com
Persons aged 65 years and above will be the fastest growing population in the Unites States
for the next four decades and are the major consumers of medications. Older adults tend to …
for the next four decades and are the major consumers of medications. Older adults tend to …